|
Gene: FGFR2 |
Gene summary for FGFR2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FGFR2 | Gene ID | 2263 |
Gene name | fibroblast growth factor receptor 2 | |
Gene Alias | BBDS | |
Cytomap | 10q26.13 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P21802 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2263 | FGFR2 | CA_HPV_1 | Human | Cervix | CC | 8.51e-05 | -1.49e-01 | 0.0264 |
2263 | FGFR2 | CA_HPV_3 | Human | Cervix | CC | 1.97e-23 | 4.50e-01 | 0.0414 |
2263 | FGFR2 | CCI_1 | Human | Cervix | CC | 6.18e-03 | 6.82e-01 | 0.528 |
2263 | FGFR2 | CCI_2 | Human | Cervix | CC | 1.04e-03 | 6.95e-01 | 0.5249 |
2263 | FGFR2 | CCI_3 | Human | Cervix | CC | 2.01e-02 | 5.07e-01 | 0.516 |
2263 | FGFR2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.06e-04 | 4.09e-01 | -0.0811 |
2263 | FGFR2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.15e-10 | 7.37e-01 | -0.1088 |
2263 | FGFR2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.90e-02 | 5.56e-01 | -0.1526 |
2263 | FGFR2 | HTA11_866_2000001011 | Human | Colorectum | AD | 8.09e-11 | 5.73e-01 | -0.1001 |
2263 | FGFR2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.04e-03 | 4.46e-01 | -0.059 |
2263 | FGFR2 | HTA11_546_2000001011 | Human | Colorectum | AD | 6.24e-03 | 5.32e-01 | -0.0842 |
2263 | FGFR2 | A008-E-015 | Human | Colorectum | FAP | 1.76e-02 | 2.45e-01 | 0.0177 |
2263 | FGFR2 | CRC-1-8810 | Human | Colorectum | CRC | 2.86e-02 | -1.80e-01 | 0.6257 |
2263 | FGFR2 | AEH-subject1 | Human | Endometrium | AEH | 1.28e-05 | 3.41e-01 | -0.3059 |
2263 | FGFR2 | AEH-subject3 | Human | Endometrium | AEH | 2.22e-08 | 3.63e-01 | -0.2576 |
2263 | FGFR2 | AEH-subject5 | Human | Endometrium | AEH | 2.41e-14 | 5.35e-01 | -0.2953 |
2263 | FGFR2 | EEC-subject1 | Human | Endometrium | EEC | 2.50e-13 | 5.55e-01 | -0.2682 |
2263 | FGFR2 | EEC-subject2 | Human | Endometrium | EEC | 1.22e-25 | 6.67e-01 | -0.2607 |
2263 | FGFR2 | EEC-subject5 | Human | Endometrium | EEC | 1.43e-05 | 2.79e-01 | -0.249 |
2263 | FGFR2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 4.88e-11 | 2.52e-01 | -0.1869 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:00018908 | Cervix | CC | placenta development | 40/2311 | 144/18723 | 4.59e-07 | 1.77e-05 | 40 |
GO:00022379 | Cervix | CC | response to molecule of bacterial origin | 78/2311 | 363/18723 | 5.55e-07 | 2.06e-05 | 78 |
GO:00324969 | Cervix | CC | response to lipopolysaccharide | 74/2311 | 343/18723 | 9.15e-07 | 3.25e-05 | 74 |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
GO:004873210 | Cervix | CC | gland development | 84/2311 | 436/18723 | 1.93e-05 | 3.54e-04 | 84 |
GO:00309019 | Cervix | CC | midbrain development | 26/2311 | 90/18723 | 2.12e-05 | 3.82e-04 | 26 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0523010 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0521512 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa0401411 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0523013 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa05215 | Colorectum | AD | Prostate cancer | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
hsa01521 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Cervix | ADJ |
FGF1 | FGFR2 | FGF1_FGFR2 | FGF | Cervix | CC |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Cervix | CC |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | CRC | ADJ |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | CRC | CRC |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | Endometrium | ADJ |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | Endometrium | AEH |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | Endometrium | EEC |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Endometrium | EEC |
FGF1 | FGFR2 | FGF1_FGFR2 | FGF | HNSCC | OSCC |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | HNSCC | OSCC |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | HNSCC | OSCC |
FGF18 | FGFR2 | FGF18_FGFR2 | FGF | HNSCC | OSCC |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | HNSCC | Precancer |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | HNSCC | Precancer |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | AAH |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | ADJ |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | AIS |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | IAC |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | Precancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FGFR2 | SNV | Missense_Mutation | rs779423644 | c.364G>A | p.Val122Met | p.V122M | P21802 | protein_coding | deleterious(0.01) | possibly_damaging(0.902) | TCGA-3C-AALJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FGFR2 | SNV | Missense_Mutation | c.338N>C | p.Val113Ala | p.V113A | P21802 | protein_coding | tolerated(0.52) | benign(0.1) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
FGFR2 | SNV | Missense_Mutation | c.1763N>G | p.Ser588Cys | p.S588C | P21802 | protein_coding | tolerated(0.31) | possibly_damaging(0.857) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
FGFR2 | SNV | Missense_Mutation | c.785N>C | p.Leu262Pro | p.L262P | P21802 | protein_coding | deleterious(0.01) | probably_damaging(0.937) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FGFR2 | SNV | Missense_Mutation | novel | c.1904N>C | p.Val635Ala | p.V635A | P21802 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGFR2 | SNV | Missense_Mutation | rs121913474 | c.1147T>C | p.Cys383Arg | p.C383R | P21802 | protein_coding | deleterious(0.02) | possibly_damaging(0.865) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGFR2 | SNV | Missense_Mutation | c.1650T>G | p.Asn550Lys | p.N550K | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FGFR2 | SNV | Missense_Mutation | c.1099N>C | p.Glu367Gln | p.E367Q | P21802 | protein_coding | tolerated(0.19) | benign(0.156) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
FGFR2 | SNV | Missense_Mutation | rs121913476 | c.1650T>A | p.Asn550Lys | p.N550K | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
FGFR2 | SNV | Missense_Mutation | c.1414G>T | p.Asp472Tyr | p.D472Y | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | FULVESTRANT | FULVESTRANT | 24448819 | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | FGFR INHIBITOR AZD4547 | 27179038 | ||
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | AEE-788 | AEE-788 | ||
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | E7090 | E-7090 | 18552176,27535969 | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | Palifermin | PALIFERMIN | ||
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | BAY1187982 | 27543601 | ||
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | BGJ398 | INFIGRATINIB | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | DOVITINIB | DOVITINIB | 24448819 | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | CHEMBL1980391 | RG-1530 | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | 354702261 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |